After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for meds like Ozempic and Zepbound has decreased.

Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Zepbound (tirzepatide): Recently approved ... Eli Lilly may face pricing pressures and challenges in maintaining its market share. Additionally, the potential entry of oral GLP-1 medications ...

Recognizing these challenges ... will benefit from streamlined access to Zepbound® vials, and can take advantage of Gifthealth's transparent pricing and nationwide delivery — key factors ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

The University of Chicago researchers found that for these drugs to meet common cost standards, the price of Wegovy would need to fall by more than 80% to $127 per month, and Zepbound’s price ...